Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)
Clinical trial NCT02341599 · COMPLETED
Trial details
- NCT number
- NCT02341599
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-11
- Primary completion
- 2015-04-13
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.